ConductScience.org, home

Paper42583201

Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands.

Bosch F and 7 others. J Thorac Dis, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands. Papers, record 42583201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42583201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands.
PubMed
Journal
J Thorac Dis
PubMed
Year
2026
PubMed
Publication types
Letter, Comment
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bosch FFlorishttps://orcid.org/0000-0002-1286-5402
2Eekhout DDave
3Knegjens JJoost
4de Jaeger KEAKatrien E A
5Tissing-Tan CJACaroline J A
6Peters MMax
7Hurkmans CCoen
8Belderbos JJosé

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on41660477BID-ding wars: will dose-escalated twice daily radiotherapy for limited stage small cell lung cancer be the new standard of care?-critical analysis of the literature.https://conductscience.org/library/papers/41660477

Source PubMed

Download CSV of comments and corrections

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128642008Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.Lancet Oncol2017https://conductscience.org/library/papers/28642008PubMed
239638533Time to escalate quality assurance in small-cell lung cancer radiotherapy trials.Lancet Respir Med2024https://conductscience.org/library/papers/39638533PubMed
341660477BID-ding wars: will dose-escalated twice daily radiotherapy for limited stage small cell lung cancer be the new standard of care?-critical analysis of the literature.J Thorac Dis2026https://conductscience.org/library/papers/41660477PubMed
438583494Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys2024https://conductscience.org/library/papers/38583494PubMed
540258573High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial.J Thorac Oncol2025https://conductscience.org/library/papers/40258573PubMed
641932500ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.Radiother Oncol2026https://conductscience.org/library/papers/41932500PubMed
736623230High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.J Clin Oncol2023https://conductscience.org/library/papers/36623230PubMed
839146944
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.
Lancet Respir Med2024https://conductscience.org/library/papers/39146944PubMed
939268857Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.N Engl J Med2024https://conductscience.org/library/papers/39268857PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42583201

GET https://conductscience.org/api/papers/v1/42583201/authors